FDA Upgrades Vitruvias Thyroid Tablet Recall to Class I Over Potency Concerns
The FDA has upgraded a recall of Vitruvias Therapeutics 30 mg thyroid tablets to Class I, its highest risk level, due to findings that the pills may be superpotent. Approximately 1,900 units distributed nationwide between January and September 2025 are affected. Consumers should not stop taking the medication without consulting a doctor, as overactive thyroid symptoms can occur.